CD274 and alveolar soft part sarcoma: Atezolizumab, an anti-programmed death ligand-1 (PD-L1) agent, received FDA approval for the treatment of adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft-part sarcomas (ASPS), following promising results from an investigator-initiated, multicenter, single-group, phase 2 study [82].